Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis

BACKGROUND: Rituximab is safe and effective for treating relapsing–remitting multiple sclerosis (RRMS) according to phase II and observational studies. There are limited data on disease activity after discontinuation and dose reduction. The objective of this study was to evaluate the effects on infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Boremalm, Malin, Sundström, Peter, Salzer, Jonatan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818716/
https://www.ncbi.nlm.nih.gov/pubmed/33475825
http://dx.doi.org/10.1007/s00415-021-10399-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818716/
https://www.ncbi.nlm.nih.gov/pubmed/33475825
http://dx.doi.org/10.1007/s00415-021-10399-8

Ejemplares similares